Article Versions Notes

Aloqbi AA, Alahdal H, Alqosaibi AI, Alnamshan MM, Al-Dhuayan IS, Al-Eidan AA, Alzahrani HAS, ALaqeel NK, Alsharif FH, Al Tuwaijri A. Lucidin from Rubia cordifolia Outperforms FDA-Approved Lapatinib as a Potential Multitargeted Candidate for Breast Cancer Signalling Proteins. Pharmaceuticals. 2025; 18(1):68. https://doi.org/10.3390/ph18010068

Aloqbi, Akram Ahmed, Hadil Alahdal, Amany I. Alqosaibi, Mashael M. Alnamshan, Ibtesam S. Al-Dhuayan, Ahood A. Al-Eidan, Hind A. S. Alzahrani, Nouf K. ALaqeel, Fatmah Hazza Alsharif, and Abeer Al Tuwaijri. 2025. "Lucidin from Rubia cordifolia Outperforms FDA-Approved Lapatinib as a Potential Multitargeted Candidate for Breast Cancer Signalling Proteins" Pharmaceuticals 18, no. 1: 68. https://doi.org/10.3390/ph18010068

Aloqbi, A. A., Alahdal, H., Alqosaibi, A. I., Alnamshan, M. M., Al-Dhuayan, I. S., Al-Eidan, A. A., Alzahrani, H. A. S., ALaqeel, N. K., Alsharif, F. H., & Al Tuwaijri, A. (2025). Lucidin from Rubia cordifolia Outperforms FDA-Approved Lapatinib as a Potential Multitargeted Candidate for Breast Cancer Signalling Proteins. Pharmaceuticals, 18(1), 68. https://doi.org/10.3390/ph18010068